Novo Nordisk Receivables 2012-2026 | NVO

Novo Nordisk receivables for the quarter ending March 31, 2026 were $15.702B, a 28.85% increase year-over-year.

  • Novo Nordisk receivables for 2025 were $13.503B, a 6.53% increase from 2024.
  • Novo Nordisk receivables for 2024 were $12.675B, a 15.99% increase from 2023.
  • Novo Nordisk receivables for 2023 were $10.928B, a 34.2% increase from 2022.

Novo Nordisk Receivables 2012-2026 | NVO

  • Novo Nordisk receivables for 2025 were $13.503B, a 6.53% increase from 2024.
  • Novo Nordisk receivables for 2024 were $12.675B, a 15.99% increase from 2023.
  • Novo Nordisk receivables for 2023 were $10.928B, a 34.2% increase from 2022.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$887.6B
Johnson & Johnson (JNJ)$574.4B
AbbVie (ABBV)$367.7B
Roche Holding AG (RHHBY)$318.8B
Merck (MRK)$299.9B
Novartis AG (NVS)$294B
Pfizer (PFE)$153.1B
Sanofi (SNY)$114B
Bayer (BAYRY)$46.2B
Innoviva (INVA)$1.8B